Abstract Body

PML is a severe demyelinating disease occurring in advanced HIV infection, caused by the reactivation of poliomavirus JC (JCV). In absence of specific anti JCV therapy, immunity restoration induced by effective combined antiretroviral treatment (cART) is a possible treatment strategy. The rationale on Pembrolizumab (PEM) use for treatment of PML is the inhibition of programmed cell death protein 1 (PD-1) potentially improving anti JCV-specific response with consequent JCV clearance.

We used PEM (2 mg/kg/iv every 4 wks) with cART for treatment of PML. The drug was given on a compassionate-use basis and all patients (pts) provided written informed consent. At each administration were performed clinical evaluation, MRI and laboratory testing, including immunophenotyping (CD3, CD4, CD8, PD-1 markers) in blood and CSF by flow cytometry. JCV specific T-cells response was analysed by Elispot assay after stimulation with JCV peptides. HIV-1 RNA was quantified with the Aptima® HIV-1 Quant Dx assay (Hologic) with a LoQ of 30 cps/ml, JCV DNA by an in house RealTime PCR method on LightCycler (Roche), targeting VP1, with LoD of 150 cps/ml.

At present, 5 HIV+ pts enrolled: 4 male, median age 43 yrs (29-52), median CD4 and CD8 count 150 (15-158) and 973 (354-1250) cell/mm3, respectively; median JCV-DNA and HIV-RNA in CSF/plasma pairs 9,540/1,503 cps/mL and 2,230/619 cp/mL. All pts received at least two doses, with a maximum of seven doses (in pt1). After treatment, we observed a JCV-DNA decline in all pts (median change -0.42, -1.64, -0.09 log). 3/5 pts showed a stability of the clinical picture and neuroimaging (pt1, pt3 and pt4), and two others died (pt2 and pt5). PD-1 expression was high in circulating CD4 and CD8 at baseline, gradually decreased over time and remained stable at low level in all patients. Expression of PD-1 in CSF was higher than in the peripheral blood, even though lower after PEM. All pts experienced an improvement of JCV-specific T cell response after PEM that paralleled PD-1 decrease and JCV-DNA decay both in CSF and in plasma; all pts still alive showed undetectable JCV-DNA values in both compartments.

According to these preliminary data, JCV-DNA quantitative reduction, PD-1 down regulation and enhanced JCV-specific T-cell response after pembrolizumab was observed, even though clinical and radiological response remained poor. More data are needed in order to identify predictors of response to therapy.